Novartis (NVS) subsidiary Novartis Pharma signed an exclusive worldwide license and collaboration agreement with Ratio Therapeutics to develop a radiotherapeutic candidate that targets somatostatin receptor 2, or SSTR2, tumors, Ratio said Monday.
Ratio said it will receive up to $745 million in upfront and potential milestone payments, along with tiered royalty payments.
Ratio said the collaboration will build on its radioligand therapy discovery and focus on preclinical activities to select a development candidate. Novartis will handle all remaining development, manufacturing, and commercialization activities, Ratio added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments